Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
Obesity Drug Deal: Trump Cuts Prices for Patients
The landmark obesity drug deal announced by Trump aims to make weight management drugs more affordable for millions of patients.
GLP-1 Drugs Lower Cancer Rates in Weight Loss Study
Find out how GLP-1 drugs like Ozempic and Wegovy can lower cancer risk while aiding in weight loss and diabetes control.
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Novo Nordisk implements a hiring freeze as layoffs approach after Wegovy's success. Discover the impact on the pharmaceutical industry.
Weight-Loss Drug Costs Fuel US Employer Healthcare Cuts
More than half of large employers in the United States are planning to reduce their healthcare benefits in 2026. This decision comes as the skyrocketing cost of new weight-loss and specialty medicines puts unprecedented pressure on budgets. The soaring costs of weight-loss drugs are a key concern, according to a new survey. The report, released…...
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.
As competition heats up, Novo Nordisk’s share price declines
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.